Equity Overview
Price & Market Data
Price: $0.052
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $1,672,663
Volume: 0
Performance Metrics
1 Week: -14.75%
1 Month: -18.11%
3 Months: -7.23%
6 Months: -15.03%
1 Year: -14.19%
YTD: 12.55%
Details
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.